Peripheral Nerve Society

08/12/2026

🎧 New Episode: Neuroimmune Crosstalk & Inflammation in CIPN with Dr. Grace Shin
How do immune mechanisms and skin microenvironments drive chemotherapy-induced peripheral neuropathy?
In this scientific dive on the Peripheral Nerve Podcast, hosts Prof. Susanna Park (University of Sydney) and Dr. Paola Alberti (University Milano-Bicocca) welcome Assistant Professor Grace Shin from the Ohio State University Department of Neurology & Comprehensive Cancer Center.
Dr. Shin shares cutting-edge insights into: 🔹 The role of microglia and macrophages in driving CIPN 🔹 Pathological changes in the skin environment during neurotoxic chemotherapy 🔹 Potential biomarkers and neuroimmune therapeutic targets
👉 Listen to the episode & explore recommended papers: https://sites.libsyn.com/572790/neuroimmune-crosstalk-and-inflammation-in-chemotherapy-induced-peripheral-neuropathy; www.pnsociety.com
Learn how to join the Traumatic and Toxic Neuropathy Consortium (TTNC)!

08/05/2026

JPNS Monthly Spotlight: This study explores the link between chronic inflammatory demyelinating polyneuropathy (CIDP) and monoclonal gammopathy of undetermined significance (MGUS). It assesses clinical phenotypes and treatment responses. https://bit.ly/4aVlDvL
IgG MGUS is significantly more common in CIDP patients, at 9%, compared to matched neurological controls at 3%. However, the prevalence of IgM and IgA paraproteins did not significantly differ between the two groups.
When comparing CIDP patients with and without IgG MGUS, those with IgG MGUS less often had an acute clinical presentation. They also more frequently experienced sensory deficits and showed prolonged distal compound muscle action potential duration
Despite these clinical differences, first-line treatment response rates were highly comparable. Eighty percent of patients with IgG MGUS responded to treatment, compared to 67 percent of CIDP patients without MGUS.
The study concludes that while IgG MGUS is associated with CIDP, its presence does not create a distinct subgroup with unique clinical features or treatment implications. First-line treatments remain equally effective for both patient groups.

07/14/2026

Chemotherapy-induced peripheral neurotoxicity (CIPN) remains one of the most common and challenging complications of cancer treatment. While we've made great strides in understanding it, measuring treatment success and finding effective therapies are still major hurdles.
In the latest episode, Professor Susanna Park and Dr. Paola Alberti sit down with Professor Jennifer Gewandter—an internationally recognized expert in pain research, peripheral neuropathy, and clinical trial methodology. 🧠✨
Together, they dive deep into how researchers evaluate CIPN and discuss how clinical trials can be redesigned to better reflect what matters most to patients.
👇 Tune in now to listen to this crucial conversation! https://sites.libsyn.com/572790/clinical-translation-and-symptom-management-in-chemotherapy-induced-peripheral-neuropathy

07/10/2026